Navigation Links
Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
Date:5/1/2013

SALT LAKE CITY, May 1, 2013 /PRNewswire-iReach/ -- Tolero Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, today announced that it has entered into a license agreement with Sanofi in which it received exclusive worldwide rights to develop and commercialize alvocidib (flavopiridol). Alvocidib is a small molecule inhibitor of the cyclin-dependent kinases that has demonstrated activity in clinical trials in several malignancies, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Under the terms of the agreement, Tolero Pharmaceuticals will pay Sanofi an undisclosed upfront payment, and future payments on the successful achievement of milestones related to the commercialization of alvocidib. Sanofi will also receive tiered royalties on sales of alvocidib and maintains certain negotiation rights with respect to manufacturing the pharmaceutical product for Tolero and becoming a commercialization partner.

"We are tremendously excited about this new opportunity and feel fortunate to partner with Sanofi on this highly promising asset with near-term commercialization potential," said Dallin Anderson , Chairman and President of Tolero.

Dr. David Bearss , Tolero's Chief Executive Officer, added, "Alvocidib has been evaluated in more than forty Phase I and Phase II clinical trials and has demonstrated remarkable activity in multiple studies of acute and chronic leukemia as both a single agent and in combination with chemotherapy." Tolero continues to advance various preclinical assets targeting areas of unmet need and strong commercial opportunity in the treatment of various cancers.

About Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has utilized its innovative drug development platform to create a diverse portfolio of candidate agents targeting multiple cancer-associated cellular pathways. Tolero Pharmaceuticals is a privately held company headquartered in Salt Lake City, Utah. For additional information, please visit the company's website at www.toleropharma.com.

Media Contact: Dallin Anderson Tolero Pharmaceuticals, Inc., 801-285-7570, danderson@toleropharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Tolero Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... WASHINGTON , Jan. 19, 2017 Conference Call and ... VNDA ) today announced it will release results for the ... market closes. ... Vanda will host a conference call at 4:30 PM ET on ... quarter and full year 2016 financial results and other corporate activities. ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in ... its owner and founder. As Oat is recognized globally as one of the healthiest ... as he believes it is a move to sow the seed of good karma. ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
(Date:1/21/2017)... Santa Rosa, CA (PRWEB) , ... January 21, ... ... announce the opening of its new medical office in Petaluma, located at 167 ... full-service casting room, access to SRO sports medicine and rehabilitation services ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... MD (PRWEB) , ... January 20, 2017 , ... A ... to donate items they no longer use or need, from clothes to couches to ... any unwanted items and take them to the nearest Goodwill donation center through February ...
Breaking Medicine News(10 mins):